After fibrin polymerization, activated Factor XIII catalyzes the formation of intermolecular cross-links between '-ychain pairs and also among two or more a-chains to form polymers. In this report we characterize the size and heterogeneity of a-chain polymers, establish the role of high concentrations of Factor XIII in determining the extent and rate of a-polymer formation, and also provide evidence that the Factor XIII required can be provided by platelets. Fibrin prepared from purified fibrinogen or platelet-deficient plasma contained a series of cross-linked a-chain polymers with M, from 140,000 to 770,000 with a mean Mr difference of 32,000 consistent with a staggered, overlapping addition of monomers to the growing a-polymer chain. In plasma containing no platelets, a-polymer formation was incomplete with residual a-monomer remaining, but higher platelet counts facilitated more rapid cross-linking into larger polymers. Purified Factor XIII was equally effective as platelets in facilitating cross-linking. We conclude that cross-linked a-polymer chains are heterogeneous in size reaching a molecular weight of several million and that high concentrations of Factor XIII as provided by platelets are required for maximum cross-linking.
Introduction
The thrombin-catalyzed cleavage of fibrinopeptides from fibrinogen results in the formation of fibrin monomer that then self-assembles into a polymer through noncovalent interactions (1) . Activated Factor XIII stabilizes the fibrin gel through formation of intermolecular e-(y-glutamyl) lysine covalent cross-links (2) . One set of cross-links forms rapidly between two '-chains of adjacent fibrin monomers with reciprocal antiparallel bonding between residues lys 406 and gln 398 near the carboxy terminus of the chain (3). Cross-linking of a-chain differs in its slower rate and greater complexity, with each a-chain forming a cross-link with up to two other a-chains, resulting in the formation of large polymers (4-7). The donor lys residues are located near the carboxy terminus of the achain and the acceptor gin residues, in the middle region (8-1 1), but the sequence and precise location of bonds formed during polymer formation have not been identified. The Plasma Factor XIII is an inactive enzyme precursor that circulates as a tetramer of two pairs of nonidentical a and b chains (15, 16) . Activation of the zymogen is initiated by thrombin cleavage of a peptide from the two a chains that then dissociate from the b chains in the presence of calcium ions to form the active enzyme (15) (16) (17) (18) . Factor XIII is also found in the soluble fraction of platelets that normally contain 50% of total blood Factor XIII activity (19) (20) (21) (22) . Plasma and platelet activated Factor XIII have the same enzymatic properties, but the platelet proenzyme differs from the plasma form in that it is composed of only a chain dimers (without b chains) (15, 16) .
The contribution of a-chain polymer structure and size to fibrin strength and plasmin resistance is well established (23) (24) (25) , as is the large potential size of a-polymers, based upon their nonentry into 5 or 7.5% polyacrylamide gels (4, 5) . However, little is known of their polymeric structure or of the approximate upper limit of size of cross-linked a-chains in fibrin clots. In the present work, we have evaluated the size and heterogeneity of a-polymers in cross-linked fibrin prepared in vitro from fibrinogen and from plasma. A series of polymers is identified, including those of relative molecular weight equivalent to and exceeding those of plasma vWf multimers. The rate and extent of a-chain polymerization are found to be significantly influenced by Factor XIII concentrations above those found in normal plasma, whether provided by platelets or by additional purified Factor XIII. Since such high concentrations of Factor XIII would be available in vivo in regions of high platelet accumulation, formation of these polymers may significantly influence physiologic hemostasis and pathologic thromboembolic phenomena. (27) and expressed in relation to pooled normal plasma defined as 100%. Purified fibronectin was prepared from pooled normal plasma by gelatin Sepharose chromatography (28) and its concentration determined by measurement of optical density at 280 nm using an extinction coefficient of 12.8 (29). Fibrinogen and Factor XIII were depleted offibronectin by gelatin Sepharose chromatography and showed no fibronectin band on overloaded reduced SDS-7% polyacrylamide gels. Cross-linked fibrin polymers were prepared by incubation of purified fibrinogen with low concentrations of thrombin as described by Connaghan et al. (30) , and gluteraldehyde-cross-linked IgM polymers were prepared as described by Martin and colleagues (31) . Bovine serum albumin and leupeptin were purchased from Sigma Chemical Co. (St. Louis, MO). Cross-linked fibrin digests containing fragments DD and DY were prepared as described previously (32) . Goat antihuman fibrinogen and peroxidase-conjugated IgG fraction rabbit anti-goat IgG were obtained from Cappel Laboratories (Cochranville, PA).
Methods
Radiolabeling. Fibrinogen was labeled with the iodogen technique (33) to a specific activity of 0.5 AtCi/mol using 0.02 mg of iodogen and 100 UCi 125I/ml of fibrinogen (20 mg/ml), and unbound 1251 was separated by gel filtration chromatography on Sephadex G25 (Pharmacia Fine Chemicals, Piscataway, NJ). Labeled fibrinogen was 93% clottable and showed the same electrophoretic mobility on SDS-7% polyacrylamide gels after disulfide bond reduction.
Blood collection andprocessing. After obtaining informed consent, Electrophoresis. Electrophoresis in SDS-7% polyacrylamide gels was performed as described by Weber and Osborn (34) . Polyacrylamide gradient gels of2.2-6.5% were prepared, as described (35) , using a gradient former (Model 570; Instrumentation Specialties Co., Lincoln, NE) with a 2% stacking gel utilizing a sulfate-borate discontinuous buffer system (36). Acrylamide and bisacrylamide were obtained from Bio-Rad Laboratories (Richmond, CA), and SDS for all purposes was obtained from Sigma Chemical Co. and recrystallized from ethanol for use. SDS-2% agarose gels were made using agarose (Seakem ME agarose) from FMC Corp. (Rockland, ME), as described (30) . Protein staining was with Coomassie Brilliant Blue (Fisher Scientific Co., Allied Corp., Pittsburgh, PA), and autoradiograms were prepared from dried gels using Kodak X-omat (XAR-2) film (Eastman Kodak Co., Rochester, NY) with exposure times of 16-120 h. Fibrin was dissolved for electrophoresis with disulfide bond reduction by incubating in the SDS containing diluent appropriate for the gel system used at 600C for 2-16 h. Western blotting was performed by a modification (37) of the method described by Towbin et al. (38) . Multimeric analysis of plasma vWf was performed in 2% agarose gels using a modification (30) ofthe method described by Hoyer and Shainoff (39) .
Results
The polypeptide chain composition of cross-linked fibrin was characterized by SDS electrophoresis using both acrylamide and agarose systems. In 7% polyacrylamide (Fig. 1 A) Electrophoresis in 2.2-6.5% polyacrylamide gradient gels ( Fig. 1 B) separated the nonentering band seen on 7% gels into a discrete series of bands migrating more slowly than the yy, all of which reacted with antifibrinogen antiserum after Western blotting. Of 21 distinct bands, there were 5 heavy doublet bands at Mr of 140,000-260,000, 5 faint bands with M, between 280,000 and 360,000, and at least 11 prominent bands migrating with apparent Mr of 420,000-700,000. The mean Mr difference between individual bands was 32,000±12,000 (SD) with an Mr range of 20,000-60,000. Clots made with fibrinogen and Factor XIII, both of which had been depleted of fibronectin, had the same gel pattern (not shown).
Incubation of clots made from fibrinogen or PDP for > 3 h resulted in a blurred band pattern, and a greater proportion of more slowly migrating protein appeared. This progression was most evident with SDS-2% agarose gels ( Fig. 1 C) . At least 6 individual faint bands could be identified between the yy band and the 680,000-mol-wt marker at 16 h, and some protein migrated at least as slowly as cross-linked trimer of IgM (Mr of 2,750,000), which was the largest molecular weight marker used. The extent of a-chain cross-linking in fibrin prepared from plasma was influenced by the platelet count. Compared with fibrin clots of PDP with a platelet count between 30,000 and 60,000/h ( Fig. 1 C) , fibrin prepared from PRP (platelet count 700,000/h) showed larger a-polymer forms (Fig. 2) .
These encompassed the range of sizes of vWf multimers and also a portion that migrated more slowly than the largest normal plasma vWf multimers and some that even failed to enter the 2% agarose gel.
In fibrin prepared from plasma with low platelet counts, cross-linking of a-chains was incomplete, with residual amonomer still present (Fig. 3) . Radiolabeled fibrinogen was added to the clotting mixture so that fibrinogen-derived protein could be distinguished from other plasma proteins by autoradiography and to enable quantitation of polypeptide chains after gel slicing. The autoradiograms showed complete y-dimerization in all clots and no changes in the (-chain due to cross-linking. However, residual a-monomer chains present in clots prepared in the absence of platelets progressively decreased with platelet counts of 200,000/,1l and 420,000/id and were very faint in clots with a platelet count of 900,000/l. The amount of the largest a-polymers increased progressively at higher platelet counts in proportion to the decrease in amonomer. Intermediate a-polymers, which entered the gel but migrated more slowly than the y-y-chain, were also less prominent in clots prepared with higher platelet counts of420,000/pu1 and 900,000/,gl. The pattern was identical in clots in which the platelets had been lysed by freezing and thawing before clot preparation (not shown). To quantitate the change in a-monomer, the gels were cut up and individual slices counted. The proportion of a-monomer was 43% in clots prepared with no platelets, and progressively less in fibrin prepared at higher 1460 C. W. Francis platelet counts, reaching a minimum of 13% at 900,000/,l ( Fig. 3 B) .
The effect of platelet count on the rate as well as the extent of a-polymer formation is shown in Fig. 4 700,000/Ml) to which 125I radiolabeled fibrinogen was added and clotted for 3 h. Both gel strips are from the same gel and the location of the application wells is indicated as "Origin." Changes in size during separate processing account for the difference in gel length. agarose gels. A greater proportion of progressively larger apolymer chains was seen in fibrin prepared from plasma at higher platelet counts. At platelet counts of 3,000/Ml and 11 ,000/ul a very small quantity of slowly migrating a-polymer formed; on the other hand, at platelet counts of 113,000/ml and 500,000/I there was a progressive increase in larger apolymer and at 500,000/Ml some failed to enter the gel. There was a clear trend toward higher molecular weight a-polymer forms in clots prepared for longer times, particularly those with platelet counts of 39,000/,gl and 113,000/g1. At lower platelet counts the time dependance was less evident, whereas at a platelet count of 500,000/ul extensive polymerization was already present at 1 h. At all platelet counts, maximum crosslinking was present in clots incubated for 24 h with no further increase in apparent size or change in distribution of a-polymer sizes with longer incubations of up to 5 d.
The distribution of radioactivity in gels of 8-h clots was determined after slicing and counting (Fig. 4 B) . In this gel system a-monomer and lower molecular weight a-polymer forms migrating near the yy-chain could not be clearly distinguished. However pared at varying platelet counts. The gel lanes used to prepare the autoradiograms in A were cut into slices and counted for radioactivity. The location of amonomer was identified by protein staining. Total a-chain was taken as the sum of a-monomer and all counts migrating more slowly than the Eyey-chain. migrated in gel slices 1-7, compared with 13% and 3% in clots made in the presence of 11 3,000/1l and 3,000/Ml, respectively. Correspondingly, the counts in slices 9 and 10 decreased, reflecting loss of a-monomer.
Since platelet Factor XIII could account for the difference in cross-linking, clots were prepared from plasma containing no platelets, but supplemented with purified Factor XIII (Fig.  5) . The clot prepared from plasma of a patient congenitally deficient in Factor XIII showed only partial y-chain crosslinking on 7% polyacrylamide gels consistent with a low residual Factor XIII level (now shown). Similarly, on the SDS-2% agarose gel, the 'y-dimer formation was incomplete, and there was no staining above the yy-band indicating little formation oflarge a-polymers. Fibrin prepared at 26, 54, and 80% Factor XIII concentration showed increasing amounts of a-polymer bands that were slightly larger than the yy-chain, but little of that migrated more slowly than the fibronectin subunit (M, of 220,000). At Factor XIII concentrations between 127 and 235% the amount of more slowly migrating a-polymer increased, including some protein that did not enter the gel in the 235% sample. The nonentering a-polymer was increasingly prominent in fibrin prepared with Factor XIII concentrations of 346-708%. At the highest concentrations of 600 and 708%, most of the a-polymer was of such large size that it failed to enter the 2% gel. The addition ofleupeptin (100 ;Zg/ml final concentration) during clot preparation to inhibit platelet calpain did not affect the extent of a-chain polymerization as shown in Fig. 3 nor the size of polymers (Fig. 4) .
Samples of reduced clots were also electrophoresed on SDS-7% acrylamide gels, and the proportions of a-chain migrating as monomer and polymer were determined after counting of gel slices (Fig. 6) . In Factor XIII-deficient plasma, Gel Slice (cm) Figure 4 . (A) SDS-2%-agarose electrophoresis of fibrin clots prepared with increasing platelet counts and for different incubation intervals. PRP and plasma with a platelet count of 3,000/Ad were prepared from five normal donors and mixtures made to adjust the platelet counts as shown. After addition of radiolabeled fibrinogen, clots were prepared for 1, 3, and 8 h; dissolved; and aliquots subjected to electrophoresis. A total of 60,000 counts was applied to each lane, and autoradiography was for 20 h. (B) Distribution of radioactivity in polypeptide chains of fibrin prepared for 8-h plasma clots at varying platelet counts after SDS-2% agarose gel electrophoresis. 8-h plasma clots prepared from plasma with platelet counts of 3,000/Ml, 11 3,000/4dl, and 500,000/Ml were electrophoresed as shown in A.
After staining, drying, and autoradiography, the gel was sliced at intervals and the proportion of radioactivity in each slice calculated. The -y'y-chains were located in slices 8 and 9, the a-monomer in slices 9 and 10, and #-chain also in slices 9 and 10.
78% of a-chain migrated as monomer and 22% as polymer, findings consistent with the partial yy-chain formation and indicative of a low level of Factor XIII activity. At higher Factor XIII concentrations, the proportion of a-monomer decreased progressively to a minimum of 10% at 708% Factor XIII. The polymeric a-chain forms were divided into two fractions, the largest of which were in the 1st 1- 
Discussion
Our findings demonstrate that a-polymer chains of crosslinked fibrin are heterogeneous and may be exceedingly large in size, of equal or greater molecular weight than vWf multimers, and also show that the rate and extent of a-polymer formation are critically dependent on Factor XIII concentration, especially that derived from platelets. Thus, fibrin prepared from pooled normal plasma with 100% Factor XIII concentration showed residual a-monomer (Fig. 3) and apolymer forms of smaller (Fig 4 and 5) size, whereas progressive cross-linking to larger polymeric forms required either added purified Factor XIII or higher platelet counts.
The slow formation of a-chain polymers in cross-linked fibrin was first demonstrated by McKee and colleagues (4) who also showed that y-chains are rapidly cross-linked to dimers. The large size of a-polymers has been inferred from their failure to enter 5 or 7.5% polyacrylamide gels and explained by the capacity of Factor XIII to cross-link each achain with up to two others (4-7), thereby creating the potential for unlimited size. The present study extends these findings, defining the size and heterogeneity of a-polymer chains through the use of gel electrophoretic systems of high porosity and resolution.
The heterogeneity of a-polymers is demonstrated in clots of limited a-polymerization, obtained from platelet-deficient plasma or from purified fibrinogen. Electrophoresis of the reduced fibrin in 2.2-6.5% polyacrylamide gels shows 21 a-poly-0 100 200 300 400 500 600 700 800
Factor XIII Concentration (%) Figure 6 . Proportion of monomeric and polymeric a-chain forms in fibrin prepared at increasing Factor XIII concentrations. Fibrin was prepared from plasma with varying concentrations of Factor XIII and electrophoresed in SDS-7% polyacrylamide gels. After staining, drying, and autoradiography the proportion of counts migrating in different positions was determined. The a-monomer was taken to represent counts between the 'yy-and a-chains. The largest a-polymers were those contained in the 1st I cm, and intermediate sized apolymer forms were those migrating from 1 cm to the -y7-chain position. Factor XIII concentrations were determined by assay. Factor XIII concentrations between 0 and 100% were adjusted by mixing Factor XIII-deficient plasma with pooled normal plasma containing no platelets, whereas Factor XIII concentrations above 100% were achieved by adding purified placental Factor XIII. Proportions of amonomer, intermediate polymers, and large polymers are expressed in comparison to the total a-chain content in each sample.
mer forms with M, of 140,000-770,000 (Fig. 1 B) . The large size of the polymers precludes their derivation from ,3-or 'ychains, as does the inverse correlation of a-monomer disappearance with a-polymer formation (Figs. 3 and 6 ). With longer incubation intervals the bands were less distinct and larger a-polymers formed ( Fig. 1 C) , perhaps the result of progressive cross-linking of smaller a-polymers to larger forms that could not be individually resolved on the 2% agarose gel system. The exact molecular weight of these polymeric forms ( Fig. 1 B) (8, 10) . Therefore, the polymeric series demonstrated in Fig. 1 B may represent a halfoverlap series of a-chains, with the apparent difference between successive polymers being about one-halfofthe molecular weight ofa-chain monomers. According to this scheme, the band with migration corresponding to Mr of 140,000 ( Fig. 1 B) would represent an a-chain trimer, and the dimeric form would migrate with an apparent Mr of -99,000 so that it would be obscured by the yy-bands. Up to 22 monomers would be required to reach the size of the 770,000 form and several fold more to produce the largest a-polymers of a size approximating and exceeding large vWf multimers (Fig. 2) . Additional factors must influence the electrophoretic distribu- tion since some a-polymers are more prominent, especially those of M, of 140,000-220,000 and 420,000-770,000, whereas others are present in lower amount (Fig. 1 B) . An additional source of polymer size heterogeneity may be the variability in size of a-chains in plasma or purified fibrinogen preparations due to proteolytic degradation. Fibrinogen in freshly drawn blood contains 11% degraded Aa-chains (41) , the majority of which have lost an 3,000-mol-wt fragment from the carboxy-terminal end. Cross-linking of a degraded a-chain would produce a polymer of Mr of 3,000 less than expected, but this should not affect significantly the size or electrophoretic mobility. However, degradation that cleaves the sites involved in cross-linking could limit the maximal size of a-polymers and also could explain the 10% residual uncross-linked fibrin monomer seen in fibrin clots made with high platelet counts (Fig. 3 B) or high Factor XIII concentration (Fig. 6) .
Other plasma proteins, including a2-plasmin inhibitor (12), fibronectin (13) , and vWf (14) , cross-link to fibrin achains and could contribute to structural heterogeneity. Hada and colleagues (14) found cross-linking of up to 60% ofplasma vWf into fibrin formed after clotting of normal plasma for 3 h. This would yield a maximum molar ratio of vWf 200,000-mol-wt subunit to fibrin a-chain of 1:400, considering a plasma vWf concentration of 10 ug/ml (42) and plasma fibrinogen concentration of 7.3,gM (1) . Although vWf incorporation may influence the kinetics of a-polymer formation (14) , this low molar incorporation would be unlikely to substantially alter the electrophoretic pattern. The normal plasma concentration of a2-plasmin inhibitor is 1 /M and a maximum of 30% cross-links to fibrin (12), resulting in a maximum molar ratio to a-chain of 1:50. This binding would also have little influence on the electrophoretic results. Mosher and colleagues (13) have identified cross-linked fibronectin/achain hybrids by SDS polyacrylamide gel electrophoresis of cross-linked fibrin, but fibronectin did not affect the formation of large a-polymers noted in this study, since the same results were obtained with fibronectin-depleted fibrinogen. Thus, the effect of cross-linking of vWf, a2-plasmin inhibitor, and fibronectin to a-chains would be to introduce additional heterogeneity to the a-polymers, but the low molar ratios preclude recognition of possible hybrid forms using our gel techniques.
Maximal a-chain cross-linking was facilitated by higher platelet counts or Factor XIII concentrations than are present in normal plasma (Figs. 3-6 ). In plasma containing no platelets, 43% of a-monomer remained uncross-linked in clots incubated for 3 h, but a-monomer decreased to 10% at a platelet count of 420,000/,Ol and virtually disappeared with 900,000 platelets/,ul (Fig. 3 B) . The larger a-polymers that formed at higher platelet counts (Fig. 4) did not require metabolically active or even intact platelets since the same results were obtained with platelets lysed by freezing and thawing. That this facilitation by platelets was due to their content of Factor XIII is supported by experiments using supplemental placental Factor XIII, which has the same structure as platelet Factor XIII (43) . Addition of placental Factor XIII to plasma containing no platelets resulted in an identical progressive acceleration of a-polymer formation and increase in polymer size as was obtained with platelets (Fig. 5) . The effect of platelets on cross-linking could be accounted for by their Factor XIII content considering that plasma with a platelet count of 300,000/ 1.d had 200% Factor XIII concentration. Thus, a-polymer formation at a platelet count of 500,000/,ul with a total Factor XIII concentration of 265% (Fig. 4 A) is comparable to that with a similar Factor XIII concentration provided by purified placental Factor XIII (Fig. 5) .
The effect of Factor XIII concentrations > 100% on achain cross-linking suggests a significant role in hemostasis for platelet Factor XIII. Approximately 50% of the Factor XIII content in blood is contained in platelets (21, 22) , and platelets adhere, aggregate, and form a packed mass at the site of vessel injury or thrombus formation. With such a high local platelet concentration, the potential exists at sites of hemostatic plug formation for platelets to provide the high Factor XIII concentrations necessary to support the rapid and extensive apolymer formation demonstrated in this report. Maximal speed and extent of fibrin cross-linking would contribute to effective and lasting hemostasis. On the contrary, the absence of sufficient platelet numbers would produce defective a-chain polymerization, as observed by Rodeghiero and colleagues (44) in patients with acute leukemia, and possibly contribute to a bleeding diathesis.
The extent of a-chain polymer formation influences the physical properties of fibrin clots by increasing the degree of cross-linking resulting in greater rigidity and elasticity (45, 46) , and greater resistance to plasmic degradation (23-25). However, these studies assessed cross-linking with gel systems of lower resolution did not define the a-polymers ofthe size demonstrated in this report, and the effect of Factor XIII concentrations > 100% was not considered. Therefore, the functional significance of progressive a-chain cross-linking to the very large polymers demonstrated here is not known. However, clinical observations indicate that newly formed thrombi are susceptible to pharmacologic lysis with plasminogen activators, whereas older thrombi become progressively resistant (47, 48) . Possibly, the progressive cross-linking of a-chains to large molecular weight polymers dependent on high level Factor XIII concentration may be an important determinant of susceptibility of thrombi to lysis.
